SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Annovis Bio, Inc. – ‘8-K’ for 5/30/23 – ‘EX-16.1’

On:  Tuesday, 5/30/23, at 5:20pm ET   ·   For:  5/30/23   ·   Accession #:  1104659-23-66171   ·   File #:  1-39202

Previous ‘8-K’:  ‘8-K’ on / for 4/4/23   ·   Next:  ‘8-K’ on / for 6/16/23   ·   Latest:  ‘8-K’ on 4/26/24 for 4/25/24   ·   6 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/30/23  Annovis Bio, Inc.                 8-K:4,9     5/30/23   11:282K                                   Toppan Merrill/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     33K 
 2: EX-16.1     Letter re: a Change in Accountant                   HTML      7K 
 6: R1          Cover                                               HTML     49K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- tm2317351d1_8k_htm                  XML     15K 
 8: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- anvs-20230530_lab                     XML     96K 
 5: EX-101.PRE  XBRL Presentations -- anvs-20230530_pre              XML     64K 
 3: EX-101.SCH  XBRL Schema -- anvs-20230530                         XSD     12K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    34K 
11: ZIP         XBRL Zipped Folder -- 0001104659-23-066171-xbrl      Zip     18K 


‘EX-16.1’   —   Letter re: a Change in Accountant


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



Exhibit 16.1

 

 

May 30, 2023

 

Office of the Chief Accountant

Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

 

Ladies and Gentlemen:

 

We have read Annovis Bio, Inc. statements included under Item 4.01 of its Form 8-K dated May 30, 2023. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our dismissal on May 25, 2023. We are not in a position to agree or disagree with other statements contained therein.

 

Very truly yours,  
   
/s/ WithumSmith+Brown, PC  
WithumSmith+Brown, PC  
East Brunswick, New Jersey  

 

 

 

 


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:5/30/23None on these Dates
5/25/23
 List all Filings 


6 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/22/24  Annovis Bio, Inc.                 424B5       3/21/24    1:397K                                   Toppan Merrill/FA
 3/19/24  Annovis Bio, Inc.                 424B5                  1:472K                                   Toppan Merrill/FA
 3/19/24  Annovis Bio, Inc.                 424B5                  1:472K                                   Toppan Merrill/FA
 2/01/24  Annovis Bio, Inc.                 S-3                    4:768K                                   Toppan Merrill/FA
11/01/23  Annovis Bio, Inc.                 424B5                  1:360K                                   Toppan Merrill/FA
10/30/23  Annovis Bio, Inc.                 424B5                  1:363K                                   Toppan Merrill/FA
Top
Filing Submission 0001104659-23-066171   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 3:21:21.1pm ET